Enovita®
Browse all Indena’s documents about products, events, company information and so much more.
Go to section
See through science
Enovita®
Scroll to see more
Peer-reviewed science on Enovita®
Clinically proven on healty subjects
The most recent study on Enovita® included 80 healthy participants that were randomized to receive GSE supplementation or placebo twice a day for a total of 16 weeks. The principal endpoints included pressure modulation and the perception of stress and worries.1
Effective in reducing perceived stress and worries
Enovita® supplementation is associated with a general increase of mental health and quality of life (quality of life questionnaire SF-12 and mental component summary MCS12).1
Figure 1. Results from SF-12 self-administered questionnaire.
The perception of worries under Enovita® supplementation was less pronounced (Figure 2).
Figure 2. Results from PSQ self-administered questionnaire at baseline, after 8 and after 16 weeks. (Validated tool to assess subjectively experienced stress independent of a specific or objective occasion).Graphic elaboration of table 2, from ref. 1.
Promotes the maintenance of normal blood pressure1
Enovita® significantly modulated both systolic and diastolic pressure with a dose-dependent effect.1
Figure 3. A favorable effect of systolic blood pressure was observed in all groups, but the effect was significantly higher in the treatment group (p < 0.05). The effect was lower for diastolic pressure. Thus, in the two treatment groups, an effect on diastolic pressure was also observed and developed more gradually over time.1
Brings blood pressure within normal range under cardiac stress2
Enovita® can have beneficial cardiovascular effects that may support intervention strategies in conditions of cardiac stress.
In a human study, after 4 months of administration, a statistically significant and dose-dependent improvement in all endpoints (systolic pressure, diastolic pressure, laser doppler flux, heart rate, plasma-free radicals) was observed in both groups delivered with Enovita® compared to the one not receiving supplementation, with blood pressure normalizing in 93% of the higher dosage (300 mg) administrated group. Altogether, these observations suggest that Enovita® has beneficial cardiovascular effects that may support current management strategies against hypertension.
Table 1. Systolic pressure, diastolic pressure, laser doppler flux, heart rate, plasma-free radicals in the two groups administrated with Enovita® (300 mg and 150 mg) and in the one not administrated, at inclusion, 4, 8, 12, and 16 weeks.
Table 2. Subject compliance and tolerability at the end of the trial.
BIBLIOGRAPHY
1Schön C, et al. Nutrients. 13(2):654. (2021)
2Belcaro G., Ledda A., Hu S., et al., Evidence-Based Complementary and Alternative Medicine, ID 313142 (2013).
